From Flow Modulation to Resection: First in Human Combination of Liver Venous Deprivation and Balloon-Occluded Chemoembolization (LVD-B-TACE): A Case Report Demonstrating a Novel Sequential Concept

从血流调控到切除:首例人体肝静脉剥夺联合球囊阻塞化疗栓塞术(LVD-B-TACE):一例展示新型序贯概念的病例报告

阅读:1

Abstract

Curative surgical treatment of hepatocellular carcinoma (HCC) is limited to liver transplantation (LT) and liver resection (LR), but many patients are ineligible due to insufficient future liver remnant (FLR). Liver venous deprivation (LVD) induces more rapid hypertrophy than portal vein embolization (PVE) but may trigger the hepatic arterial buffer response (HABR), leading to increased arterial inflow and potentially stimulating tumor growth, especially for HCC. We report a 75-year-old male with HCC and advanced fibrosis, in whom extended LVD was followed 3 days later by balloon-occluded transarterial chemoembolization (B-TACE) to coincide with HABR, providing more selective tumor control, higher intratumoral drug concentration, and low risk of non-target embolization compared to standard TACE, which is desirable in the field of deprived livers. Within three weeks, FLR increased from 33% to 51% with degree of hypertrophy (DH) 15.8%, kinetic growth rate (KGR) 5.3%/week and relative growth rate (RGR) 47,6% accompanied by near-complete tumor response, enabling curative hepatectomy. Despite postoperative complications, R0 resection was achieved. This case illustrates the technical feasibility of sequential LVD followed by B-TACE in this specific order, suggesting that such an approach may help reduce the hepatic arterial buffer response within the tumor, support rapid hypertrophy, and facilitate resectability in carefully selected patients, including elderly individuals with comorbidities. To the best of our knowledge, and based on a comprehensive literature search, this is the first reported case of LVD-B-TACE.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。